Thursday, 6 August 2026

Indian corporate news, decoded into deal flow

NSE LIVE
NIFTY 50 — INDIA VIX —
as of —
MARKETS
DEAL FLOW
TVS Group Announces Major NBFC Restructuring:… ▲ Mergers & Acquisitions Viviana Power Tech Q1 FY27 Results:… ▲ Order Book UPL Q1 FY27 Results: Profit Returns… ▲ Capex & Future Plan Nucleus Software Launches FinnOne Neo 9.0… ▲ Capex & Future Plan Clean Science and Technology Posts Record… ▲ Results DCM Shriram International Promoter Acquires 30.07… ▲ Shareholding & Insider Moves PTC Industries’ Aerolloy Signs Landmark Airbus… ▲ Order Book
Home / Company Results / Clean Science and Technology Posts Record Q1 FY27 Sales of Rs 264 Cr
RS · Company Results

Clean Science and Technology Posts Record Q1 FY27 Sales of Rs 264 Cr

BY ADMIN • FILED 06 Aug 2026, 2:34 PM

Clean Science and Technology Limited Announced its earnings update for the first quarter of FY27, delivering its highest-ever quarterly consolidated revenue of approximately ₹264 crore. Despite macro-headwinds including elevated freight costs, vessel unavailability, and supply chain disruptions impacting export schedules, the specialty chemical manufacturer delivered a steady operational performance.

Key Financial Highlights

  • Consolidated Revenue: Reached ₹264 crore, marking a growth of 10% year-on-year (YoY) and 7% quarter-on-quarter (QoQ).
  • Consolidated Profitability: EBITDA stood at ₹96 crore (37% margin), while Profit After Tax (PAT) reached ₹73 crore (28% margin).
  • Standalone Performance: Revenue grew 5% sequentially to ₹203 crore. Standalone EBITDA reached ₹87 crore (43% margin) and PAT stood at ₹73 crore (36% margin).
  • Segment Revenue Mix: Performance Chemicals contributed 83% to sales, followed by Pharma Chemicals at 10% and FMCG at 7%.

HALS Growth & Portfolio Diversification

The company’s strategic focus on scaling its Hindered Amine Light Stabilizers (HALS) portfolio continues to drive sustainable operational leverage. HALS now accounts for 22% of total consolidated sales. In a shift from its initial domestic focus, international markets now drive nearly 50% of HALS sales. Furthermore, Clean Science has successfully derisked its portfolio, reducing revenue reliance on its top four legacy products from 85% in Q4 FY23 to 60% this quarter.

Subsidiary Turning Operational and Strategic Alliance

In another major update, Clean Science’s subsidiary, Clean Fino Chem Limited (CFCL), crossed a key benchmark by becoming operationally self-sustaining after fully recovering its operating expenses, allowing the firm to transition from investment mode to monetization mode. Additionally, the company formed a strategic partnership with Swiss partner Genus Chem to collaborate on advanced, technology-intensive HALS chemistry grades for global customers.